< All Tickers
NVO
Novo Nordisk
Earnings
NVO | Earnings Review
Novo Nordisk A/S | FY2026 Q1 reported May 6, 2026 | Analysis date: May 11, 2026 | Daloopa company_id 50204
Headline vs Adjusted Sales
DKK 96.8B / 70.1B
Reported sales DKK 96.82B includes a DKK 26.76B one-time 340B provision reversal; adjusted DKK 70.06B is the real read = -10% YoY
Adjusted Op Profit
DKK 32.86B
32.86B vs implied ~32.0B (+2.7%) — slight beat on a reset bar. Reported DKK 59.62B is reversal-distorted. -15% YoY adjusted
Wegovy Pill Ramp
DKK 2.26B in Q1
DKK 2.26B oral Wegovy in launch quarter — ~170k patients in ~3 weeks, >2x prior AOM launch pace. Wegovy injectable DKK 18.24B (+5%) softer on price/mix
The headline is fake. The signal is the 1-pt guidance bump. Reported revenue DKK 96.82B looks like a 24% YoY blowout, but is entirely a function of a one-time ~DKK 26.8B 340B provision reversal. On the adjusted (ex-reversal) basis management itself introduced this quarter, net sales were DKK 70.06B (-10% YoY) and adjusted operating profit DKK 32.86B (-15% YoY) — broadly in-line with implied consensus (+0.8% / +2.7%) on a reset bar. Wegovy injectable DKK 18.24B (+5%) was slightly soft on pricing/mix (self-pay ~30% of scripts at $199 initiation), while Wegovy pill DKK 2.26B in its first full quarter post Jan 5 launch is tracking >2x prior AOM launch pace (~170k patients in 3 weeks). GLP-1 diabetes (Ozempic + Rybelsus + Victoza) DKK 32.73B was -17% YoY — Ozempic the structural drag. The real positive is the FY2026 guide raise: sales decline tightened to -4% to -12% CER (mid -8%, from -9%), op profit decline to -4% to -12%. Symmetric 1-pt tightening = narrowing of uncertainty, not a step-up. FCF guide +DKK 1B at both ends to 36-46B; capex unchanged at DKK 55B. Tone: cautious-improvement. No 'stabilization' or 'inflection' language; CEO Doustdar maintains 'year of pricing headwinds' frame from Q4'25 with marginal operational confidence added. Watch: (1) Lilly Foundayo (orforglipron) commercial ramp post Apr 1, 2026 approval — first real competitive Rx read in Q2; (2) FDA 503B compounding exclusion comment period closes Jun 29, 2026; (3) Medicare Part D obesity coverage starts mid-2026, bigger benefit into 2027; (4) IRA negotiated Ozempic price ($274 vs $959 list, -71%) effective Jan 2027; (5) CagriSema US PDUFA late 2026 — REDEFINE 4 (Feb 2026) showed 23.0% vs tirzepatide 25.5%, non-inferiority not superiority; (6) 340B litigation outcome could reverse the Q1 reversal. Thesis read: Q1 print does NOT reset the thesis — adjusted core still negative, Ozempic still declining, MFN/pricing still early innings. Treat FY26 -4% to -12% as downside-skewed; 2027 is the implicit pivot year (capex steps down, Part D ramps, CagriSema launches, semaglutide LOE laps). Caveat: Q1'26 transcript not available via FMP; Q&A analysis below is from FY2025 Q4 call (Feb 2026).
Key Metrics Trends
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 (adj) |
|---|---|---|---|---|---|---|---|---|
| Net Sales (DKK B) | $68M | $71M | $86M | $78M | $77M | $75M | $79M | $70M |
| Net Sales (DKK B) YoY % | - | - | - | - | +12.9% | +5.1% | -7.6% | -10.3% |
| Revenue YoY % | 25.3% | 21.4% | 30.1% | 19.5% | 12.9% | 5.1% | -7.6% | -10.3% |
| Revenue YoY % YoY chg (bps) | - | - | - | - | -1240 | -1630 | -3770 | -2980 |
| Diluted EPS (DKK) | $4.49 | $6.12 | $6.34 | $6.53 | $5.96 | $4.50 | $6.04 | $6.16 |
| Diluted EPS (DKK) YoY % | - | - | - | - | +32.7% | -26.5% | -4.7% | -5.7% |
| EPS YoY % | -48.0% | 22.4% | 0.0% | 15.0% | 32.7% | -26.5% | -4.7% | -5.7% |
| EPS YoY % YoY chg (bps) | - | - | - | - | +8070 | -4890 | -470 | -2070 |
_Trajectory: decisively decelerating — from hyper-growth to outright decline in 5 quarters. Revenue YoY: Q2'24 +25.3% → peak Q4'24 +30.1% → +19.5% → +12.9% → +5.1% → -7.6% → Q1'26 adj -10.3%. Deceleration in 6 of the last 7 quarters; cumulative ~3,500 bps from peak to trough. Inflection points: Revenue peaked Q4'24; deceleration began Q1'25 (-1,060 bps QoQ — compounding leakage, Lilly Zepbound share); first outright decline Q4'25; by Q1'26 Wegovy growth (DKK 18.24B vs 17.36B PY) no longer offsets Ozempic decline (DKK 27.83B vs 32.72B PY). EPS trajectory: Held up through Q2'25 (+33% YoY on cost leverage) but turned negative Q3'25 once revenue collapsed; Q1'26 adj EPS ~DKK 6.16 marks a second consecutive YoY decline (stripping after-tax 340B reversal benefit ~DKK 4.75/sh from reported DKK 10.91). Three drivers explain the round-trip: (1) US compounding pharmacy leakage persisting post-shortage delisting, (2) US net pricing pressure (340B, MFN, cash-channel at $199, Medicaid coverage losses), (3) Lilly Zepbound/Mounjaro share gains in both obesity and diabetes. Bull case requires CagriSema/oral semaglutide commercial inflection in 2H26 or stabilization of US net pricing — neither visible in the trajectory data yet._
Beat/Miss
Guidance
Catalysts
Street Q&A
Contradictions
Read-Throughs
This Quarter vs Consensus
| Metric | Consensus (implied) | Actual | Variance | Read |
|---|---|---|---|---|
| Revenue — REPORTED (DKK B) | ~71.5 | 96.82 | +25.3 / +35% | Massive headline beat — entirely 340B reversal |
| Revenue — ADJUSTED ex-340B (DKK B) | ~69.5 | 70.06 | +0.6 / +0.8% | Slight beat — essentially in-line |
| Operating profit — REPORTED (DKK B) | ~34.0 | 59.62 | +25.6 / +75% | Reversal flows ~1:1 to OP |
| Operating profit — ADJUSTED (DKK B) | ~32.0 | 32.86 | +0.9 / +2.7% | Modest beat on core |
| Op margin % — ADJUSTED | ~46.0% | ~46.9% | +90 bps | In-line, slight beat |
| Diluted EPS (DKK) — REPORTED | ~7.50 | 10.91 | +3.4 | Reversal-driven beat |
| Diluted EPS (DKK) — ADJUSTED est. | ~5.10 | ~6.16 | +1.06 | Adjusted EPS ex after-tax reversal |
| Wegovy injectable (DKK B) | ~19.0 | 18.24 | -0.8 / -4% | Slight miss vs buy-side bar |
| Wegovy pill (DKK B) | n/a (launch Q) | 2.26 | n/m | Strong launch quarter |
| GLP-1 diabetes (DKK B) | n/a | 32.73 | -17% YoY | Ozempic structural drag |
| L8Q Revenue beat rate | — | ~50% | — | Pre-2025 near-100% → 2025 broke streak |
| L8Q EPS beat rate | — | ~75% | — | Cost actions held EPS line longer |
| L4Q Revenue beat rate (clean) | — | 1 of 4 | — | Ex-reversal basis |
| L4Q EPS beat rate | — | 4 of 4 | — | Reversal-aided in Q1'26 |
Pattern: 'Consistent beater → 2025 guide-down regime → 2026 reversal-distorted print on reset bar.' NVO went from near-automatic top- and bottom-line beater through mid-2024 into a series of material 2025 guide-downs (3 cuts in 9 months) as US obesity pricing pressure, Lilly share gains, compounder leakage, and Medicaid AOM cuts hit. Q4'25 landed on an already-reset bar (clean beat on low hurdle); Q1'26's headline beat is entirely the one-time DKK ~26.8B 340B provision reversal — the underlying adjusted core was in-line and Wegovy was slightly soft. Mgmt explanation: (1) 340B reversal flagged on Q4'25 call as 2026 event, now booked; (2) GLP-1 diabetes -17% on Ozempic share + price; (3) Wegovy softness on injectable pricing/mix (cash channel ~30% of scripts at $199), not franchise demand — combined Wegovy inj+pill NBRx >75k/wk leads AOM category; (4) Guide raise driven by Q1 volume response to lower pricing + Wegovy pill traction. The clean read: headline beat is non-cash 340B; adjusted core in-line; Wegovy slightly soft on price; the real positive is the modest guide raise.
Guidance Deep Dive
| Metric (FY26, CER unless noted) | Prior Guide Mid | New Guide Low | New Guide High | New Guide Mid | vs Prior Mid | Consensus |
|---|---|---|---|---|---|---|
| Adjusted sales growth | -9.0% | -12% | -4% | -8.0% | +1.0pp | n/a (not pulled) |
| Adjusted operating profit growth | -9.0% | -12% | -4% | -8.0% | +1.0pp | n/a |
| Capital expenditure (DKK B) | 55 | 55 | 55 | 55 | Unchanged | — |
| Free cash flow (DKK B) | 40 | 36 | 46 | 41 | +DKK 1B | — |
| Reported (DKK) vs CER drag | — | — | — | ~-3pp sales / -5pp OP | USD weakness vs DKK | — |
| Q2 2026 quarterly guide | n/a | — | — | None issued | — | — |
| Total cash returns FY26 | — | — | — | >DKK 60B + DKK 15B BB | Q4'25 commentary | — |
Tone: cautious-improvement, NOT a thesis reset. Q4'25 (initial 2026 guide) was defensive/apologetic — Doustdar: 'we have released our 2026 guidance, which reflects a year of pricing headwinds. We do not take this lightly... price reduction in some ways, is our investment for the future and for capturing more patients.' Q1'26 release tightened the band 1pp each end but did NOT call a bottom. No 'stabilization' or 'inflection' language. Symmetric 1-pt tightening = narrowing of uncertainty, not step-up in expectations. Introduction of adjusted-basis framework is itself a tone signal — mgmt wants investors to underwrite underlying performance, not optical 340B-distorted reported figures. Key risk caveats (Q4'25 verbatim, carried through Q1'26): FX (~3pp drag on reported sales, ~5pp on OP), MFN ('low single-digit impact on group sales, roughly double on US'), US pricing investment, CagriSema REDEFINE 4 'amended study... should be taken with a little bit of a risk' (non-inferiority not superiority), Medicare Part D 'limited benefit this year and a bigger benefit into 2027,' semaglutide LOE in IO markets (Canada generic risk). 2027 framed as implicit pivot year: capex steps down 'steeper slope in coming years,' Medicare Part D ramps, CagriSema US PDUFA late 2026/early 2027, REDEFINE 11 readout early 2027 with both extended duration AND flexible titration.
Upcoming Catalysts
| # | Catalyst | Timing | Consensus View / Read | Risk/Reward |
|---|---|---|---|---|
| 1 | Lilly Foundayo (orforglipron) competitive ramp | Approved Apr 1, 2026; aggressive ramp through FY26; Medicare $50/mo from Jul 1, 2026 | Buy-side views orforglipron as most direct existential threat to Wegovy pill; sell-side modeling double-digit oral GLP-1 share loss by 2027 | Risk: dominant near-term overhang — no food/water restrictions, $25-50/mo cash pay. Reward: NVO retains efficacy edge (16.6% vs 12.4% weight loss) |
| 2 | Q2 2026 earnings print | Aug 5, 2026 | First clean print since improved FY26 guide; tests whether US obesity adjusted sales stabilize ex-340B; Foundayo competitive damage visible in NRx data | Reward: another guide raise = bottom confirmed. Risk: first read on competitive damage |
| 3 | Wegovy oral US ramp | Through FY26-FY27 | Already DKK 2.26B in Q1; OASIS 4 showed 16.6% weight loss; defensive vs orforglipron | Volume could offset US net price pressure; cannibalizes injectable Wegovy |
| 4 | FDA 503B compounding final exclusion | Comment period closes Jun 29, 2026; final rule H2 2026 | Consensus expects exclusion finalized, closing legal bulk compounding of sema; 503A 4-rx/mo loophole still permits gray market | Removes multi-billion grey-market headwind; supports US Wegovy/Ozempic vols |
| 5 | CagriSema FDA decision (REDEFINE 1/2 filing) | PDUFA expected Q4 2026 | REDEFINE 4 (Feb 2026): 23.0% weight loss vs tirzepatide 25.5% — non-inferiority not superiority. Sell-side cautious post-REDEFINE 1 disappointment | Risk: head-to-head inferiority vs Zepbound undermines premium pricing. Reward: first GLP-1+amylin combo |
| 6 | IRA Medicare price negotiation — semaglutide effective | Jan 1, 2027 | Negotiated Ozempic $274/mo vs $959 list (-71%); ~2.3M Medicare Part D users; $15.2B 2024 spend base. Dave: 'more of a 2027 event' | Material US gross-to-net step-down on Ozempic/Wegovy/Rybelsus starting Jan 2027 |
| 7 | Medicare Part D obesity coverage (CMMI pilot) | Starts mid-2026; ramp; bigger benefit 2027 | Knudsen: 'limited benefit this year and a bigger benefit into 2027.' Partial offset to MFN | Offsets MFN but back-half loaded and modest in 2026 |
| 8 | Amycretin Phase 3 initiation (sc + oral) | Phase 3 starts H1-H2 2026 | Buy-side sees amycretin (22% wt loss at 36 wks in Ph1b/2a) as the real next-gen, not CagriSema; approval ~2030 | Best-in-class potential could re-rate pipeline; sentiment catalyst |
| 9 | REDEFINE 11 readout (high-dose CagriSema, full duration + flex titration) | Early 2027 | First chance to show full CagriSema weight-loss potential with both optimization vectors | Bull thesis hinge — only readout that could re-establish 'next-gen' framing |
| 10 | 340B rebate model litigation resolution | Through 2026 | Q1'26 reversal of DKK 26.8B signals NVO believes legal risk has materially declined; HRSA pilot suspended Jan 2026 pending litigation | Reward: favorable ruling validates reversal. Risk: adverse ruling could force re-establishment of provision, reversing the Q1 EPS boost |
| 11 | Capital Markets Day / new mgmt LT targets | H2 2026 (September referenced internally) | First chance for new CEO/US commercial leadership to reset 2027-2030 sales and margin algo post-CagriSema | Reward: credible algo unlocks re-rating. Risk: targets below consensus completes de-rating |
| 12 | Capital return / buyback updates | With H1 print and CMD | FCF guide raised to 36-46B; FY26 returns >DKK 60B + new DKK 15B BB | Re-acceleration signals confidence; BD could compete for capital |
| 13 | Semaglutide LOE in IO markets (Canada generics) | Through 2026 | Low-single-digit group impact; Canada biggest contributor; mgmt 'don't have detailed insights' on Health Canada deficiency notices | Real volume/price drag named in the guide |
| 14 | 7.2 mg Wegovy approval/launch under CNPV voucher | Q1-Q2 2026 | Mgmt: 'we will not sit on that regulatory approval. And we will go all in again.' ~20% weight loss approaching tirzepatide | Premium-dose label closes efficacy gap to Zepbound |
Street Q&A
| # | Analyst (Firm) | Topic | Mgmt Response (key quote) | Quality |
|---|---|---|---|---|
| — | CAVEAT | Q1'26 transcript unavailable via FMP | Q&A below is from FY2025 Q4 call (Feb 2026), most recent FULL transcript. Many same debates likely re-litigated on the May 6, 2026 call. | Caveat |
| 1 | Quigley (Goldman Sachs) | Guidance bridge & Medicare Part D pace | Karsten: US sales decline 'in the teens' driven by price (market access, cash channel mix, MFN low-SD group impact ~2x on US). 'It will be a gradual ramp with limited benefit this year and a bigger benefit into 2027.' | Well Answered — specific decomposition |
| 2 | Jain (Bank of America) | What changed vs Q3 & path to low end of guide | Karsten declined to quantify drivers of low end. 'The obesity market is just significantly more dynamic than most other markets... classic variables, but it's in a very dynamic market segment.' | Deflected/Vague |
| 3 | Vosser (JPMorgan) | Commercial formulary risk & compounder share displacement | Dave Moore: injectable access 'relatively stable.' On compounders: 'we haven't seen a change yet... it's a little bit early to tell.' 170k patients on Wegovy pill mostly self-pay | Honest but not informative — no longitudinal source-of-business data |
| 4 | Verdult (BNP Paribas) | REDEFINE 4 design & guidance conservatism / kitchen-sinking | Martin: REDEFINE 4 dosing 'similar to REDEFINE 1' — did NOT include new flex titration. 'Full weight loss potential, we will only learn when we do the full trial duration and the flexible dosing' (REDEFINE 11). Mike ducked the kitchen-sink question | Mixed — de-risks REDEFINE 4 readout (mgmt own expectations); deflects on sandbagging |
| 5 | Nedelcovych (TD Cowen) | Wegovy pill supply & CagriSema setup | Doustdar: 'we launched the pill in the US at a time where we will be confident enough to know we will not run into supply situation.' Martin: full upside is in REDEFINE 11, not REDEFINE 4 | Well Answered — direct on supply, transparent on trial setup |
| 6 | Sephton (UBS) | Pill sustainability vs orforglipron & pill gross margin | Doustdar: 'Wegovy pill gives you 16.6% weight loss... they (orforglipron) are at 12.4%.' Karsten: pill GM 'below that of the Wegovy injectable, but... still an attractive gross margin' — refused to quantify | Well Answered on efficacy; Deflected on actual pill GM |
| 7 | Boutherin (Morgan Stanley) | Ozempic MFN timing & pill adherence | Dave: 'MFN and MFP is more of a 2027 event' for Ozempic; ~8k Ozempic self-pay scripts/wk. Martin: semaglutide's long half-life means missed doses don't materially impact exposure — structural advantage over orforglipron | Well Answered — both direct, with concrete differentiation |
| 8 | Madsen (Danske Bank) | CapEx / API build & 7.2 mg launch | Karsten: 'CapEx stepping down for first time; steeper slope in the coming years.' Mike: '7.2mg... We will not sit on that regulatory approval. And we will go all in again.' | Well Answered — specific commitments |
| 9 | Baker (Rothschild & Co.) | Price visibility vs volume uplift & Canada generics | Karsten: 'For mature reimbursed brands, that's reasonably straightforward... uncertainty is in the self-pay type channel because the price elasticity in the self-pay channel is something that we are still exploring.' Canada generic: 'we don't have detailed insights' | Well Answered — explicit asymmetric visibility framing |
| 10 | Deflected/Avoided Summary | Lowest-quality answers — 4 themes | (a) Pill GM quantification (refused number); (b) Path to bottom of guidance (retreated to 'dynamic market'); (c) Kitchen-sink question on sandbagging (pivoted to methodology); (d) Compounder share gains from pill (no longitudinal data) | Most-debated stock questions ducked |
Contradictions
| # | Topic | Severity | Statement A | Statement B | Implication |
|---|---|---|---|---|---|
| 1 | Compounders winding down | HIGH — genuine reversal | Q1 2025: 'As of May 22, we fully expect the FDA to enforce the law... patients on compounded products will go to branded products in 2H' — Moore/Knudsen. Q1 2025 guide anchored to compounder unwind | Q3 2025: 'Regrettably, Novo Nordisk market research shows that compounding has continued to increase... well above 1 million patients in the US' — Moore | Largest driver of the May & Aug 2025 guide-downs. Management's read on the legal/enforcement path was overconfident. Discount future 'we have a plan' claims, especially the cash-channel build |
| 2 | CagriSema 'next-generation' framing | HIGH — product role reset | Q1 2025: CagriSema as 'next-generation obesity treatment' with Q1 2026 submission; pre-positioned as step-change over Wegovy | Q3 2025: 'Our base case has always been non-inferiority with an upside of superiority' (Lange). REDEFINE 4 (Feb 2026): 23.0% vs tirzepatide 25.5% — non-inferior, not superior | CagriSema is no longer credible answer to Lilly's pipeline; parity asset with peripheral differentiation. Metsera and Akero BD activity is the implicit acknowledgement. Internal mgmt score 4.5 |
| 3 | US pricing power 'limited additional risk' | HIGH — reality reversal | Q1 2025: 'I have to think we're in a good spot because our book of business pricing exposure is either lower or is already in ongoing price negotiations... relative limited additional risk' — Lars Jorgensen | Q3 2025: NVO accepted IRA MFP for Ozempic/Rybelsus/Wegovy for 2027 ('negative LSD impact'). Q4 2025: signed MFN agreement; FY26 guide -5/-13% CER driven by 'lower realized prices' amplified by MFN, $499 NovoCare cash channel ~30% of Wegovy injectable | US pricing is single largest negative variable. 'Limited additional risk' did not survive 9 months. Wegovy U.S. economics structurally repriced — model $499 as the floor, not a transitory promo |
| 4 | 'Commercial execution top priority' vs share loss + churn | MEDIUM-HIGH — evolving claim | Feb 2025 CMD: 'commercial execution being mgmt's top priority' — acknowledged by Lars; 'we feel honestly very confident that this is the right moment for us to make a serious change in the market' | Q3 2025: new CEO Doustdar: 'I would not lie and say I don't like losing market share... marathon, not a sprint.' ~9pp combined dia+obesity GLP-1 share loss in 12 months; 9,000-position restructuring; Dave Moore out Q4'25; 3rd major leadership reshuffle in 9 months | Asserted execution strength while KPIs all deteriorated. Internal mgmt score 4.5 well-supported. Set low bar for new 'we have a plan' claims until 2-3Q of evidence under Doustdar/Millar |
| 5 | Successive 2025 guide-downs | MEDIUM — evolving, but credibility cost | Q1'25 release: FY25 sales guide 13-21% CER (already cut). Karsten: 'acceleration to deliver our guidance is mainly in the second half... compounded products will go to branded' | Q2'25 pre-announce: cut to 8-14% CER. Q3'25: narrowed to 8-11%. Actual FY25: ~10%. Three cuts in 9 months on same root causes | Closer to legitimate evolution than reversal, but pattern of repeated misses on same root causes = systematically optimistic forecasting model. Treat FY26 -4% to -12% as downside-skewed |
| 6 | Wegovy compounding 'transitory overhang' | HIGH — long-run economics shift | Early 2025: compounding framed as one-quarter overhang resolving by May 22. 'This is the right moment for us to make a serious change in the market' — Lars | Q3-Q4 2025: compounding 'well above 1 million patients' and growing. NVO's cash channel grew to ~30% of Wegovy injectable scripts — a permanent low-priced anchor. Q1'26 Wegovy inj DKK 18.24B vs 17.36B PY = muted rebound | Wegovy US economics structurally repriced lower. Even if compounder enforcement tightens, NVO's cash-channel infrastructure (NovoCare, GoodRx, Costco, Amazon, telehealth) is now a permanent $499 anchor |
Indirect Read-Throughs
| Company | Relationship | What NVO signaled | Read-Through |
|---|---|---|---|
| Eli Lilly (LLY) | Primary obesity/diabetes competitor | Doustdar: 'Wegovy pill gives you 16.6% weight loss... they (orforglipron) are at 12.4%.' REDEFINE 4 head-to-head: CagriSema 23.0% vs tirzepatide 25.5% — non-inferior, not superior. Foundayo approved Apr 1, 2026 at aggressive $25/$50 cash pricing | MIXED — NVO loses on Zepbound efficacy comp; wins on oral peptide efficacy vs orforglipron. Industry pricing reset is real (LLY guided 'low to mid-teens' price cuts globally per Quigley) |
| Hims & Hers (HIMS) | Compounder via telehealth | Moore Q4'25: 'we haven't seen a change yet... compounding market relatively stable.' But NVO's $199 Wegovy injectable + $499 NovoCare pill = direct compounder economic attack | Near-term resilient; medium-term squeeze intact as price gap narrows. Watch 503B rule finalization Jun 2026 |
| Structure Therapeutics (GPCR) | Oral small-molecule GLP-1 | NVO's emphasis: Wegovy pill peptide-grade efficacy (16.6%) is direct read-through challenge to small-molecule oral thesis (~12%) | NEGATIVE — peptide-in-a-pill platform sets higher efficacy bar oral SMs will struggle to match |
| Viking Therapeutics (VKTX) | Pipeline competitor (dual agonist) | NVO highlighted internal triagonist (GLP-1/GIP/amylin), in-licensed UBT251, zenagamtide. Multi-shot-on-goal next-gen positioning | VKTX more takeout target than peer. NVO's ~DKK 30B 2025 BD activity keeps M&A optionality alive |
| Roche (ROG) / CT-388 | Pipeline competitor (obesity) | Not explicitly named on Q4'25 call — noteworthy silence given 'competitive dynamics' framing | Implies CT-388 not viewed as near-term commercial threat; 2027+ event |
| Amgen (AMGN) / MariTide | Pipeline competitor (monthly obesity) | Not directly named. NVO frames internal CagriSema, 7.2mg sema, zenagamtide, triagonist as relevant 2026-27 frontier — not MariTide | Neutral-to-slightly-negative for AMGN positioning narrative |
| Pfizer (PFE) / danuglipron | Former pipeline competitor | Not mentioned; Wegovy pill >2x prior AOM launch pace | PFE's danuglipron discontinuation was the right call; far behind in metabolic |
| CVS Caremark | PBM / Wegovy pill formulary partner | Moore: 'commercial access for the Wegovy pill is progressing with coverage currently via CVS, Prime, Optum and Anthem' | POSITIVE — early formulary partner; PBM relevance grows as MFN/CMMI rolls in |
| Express Scripts / Cigna | PBM | NOT named in early Wegovy pill formulary panel | Notable absence — possible negotiation overhang |
| UnitedHealth / Optum (UNH) | PBM / payer; talent | Optum named as early Wegovy pill formulary partner. New EVP US Operations Jamey Millar joined from 'UnitedHealth Group, CEO of Optum Specialty Holdings' | Strategic hire signals serious US market-access push. Neutral for UNH |
| Anthem (Elevance / ELV) | Payer | Listed as Wegovy pill commercial coverage partner | Confirms participation in oral AOM coverage |
| Amazon Pharmacy | DTC distribution | Moore: 'expansion of direct-to-patient initiatives like the recently announced collaboration with Amazon Pharmacy' | POSITIVE for Amazon's specialty/cash-pay positioning vs traditional retail |
| Telehealth GLP-1 prescribers (Ro, LifeMD, Noom) | Distribution partners | Moore: 'Wegovy Pill offered at over 70k retail pharmacies and through NovoCare Pharmacy and numerous telehealth partners' | POSITIVE for Ro/LifeMD with NVO partnerships; NEGATIVE for telehealth still reliant on compounded sema |
| Catalent (acquired) | Supplier — now internal | Knudsen: 'amortization and depreciation related to the acquisition of the 3 Catalent manufacturing sites' | Peptide fill-finish capacity tight enough to justify in-housing — read-through to broader CDMO landscape |
| Progressive (PGR) / Allstate (ALL) | Auto insurance analog (pricing) | Industry-wide pricing reset (NVO guided 'low to mid-teens' global price cuts referenced) | Limited direct read; industry pricing dynamics common theme |
Data sourced from Daloopa. Document search is currently in beta; transcript and filing snippets may vary.